CCTA-1523

Cat. No.:	HY-129301
CAS No.:	1616271-41-0
Molecular Formula:	$C_{16}H_{15}Cl_2NO_3$
Molecular Weight:	340.2
Target:	BCRP
Pathway:	Membrane Transporter/Ion Channel
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	CCTA-1523 is a potent, selective, reversible and orally active ABCG2 inhibitor. CCTA-1523 shows cytotoxicity. CCTA-1523 shows anticancer activity[1].
In Vitro	CCTA-1523 (0-1000 μM; 72 h) shows cytotoxicity for H460, H460/MX20, HEK293/pcDNA3.1, HEK/R482, HEK/R482G and HEK/R482T cells[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	CCTA-1523 (75 mg/kg; p.o.; q3d x 6) combined with doxorubicin (HY-15142A) (1.8 mg/kg, i.p., q3d X 6) inhibits tumor growth and increases the survival time in mice[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	NCR nude mice (H460/MX20 xenografts)[1]
Dosage:	75 mg/kg (DOX ;1.8 mg/kg, i.p., q3d X 6)
Administration:	P.o.;q3d x 6
Result:	Significantly inhibited the growth of H460/MX20 tumor xenografts when combined with doxorubicin compared to the vehicle control group.

REFERENCES

[1]. Patel A,et al. Suppression of ABCG2 mediated MDR in vitro and in vivo by a novel inhibitor of ABCG2 drug transport. Pharmacol Res. 2017 Jul;121:184-193.

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA